NATCO Pharma Secures Tentative US FDA Approval for Generic Olaparib Tablets

NATCO Pharma Limited has received tentative approval from the U.S. FDA for Olaparib tablets in 100 mg and 150 mg strengths, confirming the products are bioequivalent to AstraZeneca’s reference listed drug (RLD), Lynparza®. The approval covers the indications included in the approved U.S. prescribing information. NATCO will manufacture the tablets, while Alembic Pharmaceuticals Limited will commercialize and distribute the product in the United States once final regulatory and legal requirements are satisfied.

Expanding Access to an Established PARP Inhibitor

Olaparib is an oral poly (ADP-ribose) polymerase (PARP) inhibitor used to treat several BRCA-mutated and homologous recombination deficiency (HRD)-associated cancers. In the United States, it is approved for multiple oncology indications, including selected patients with ovarian, breast, pancreatic, and prostate cancers.

PARP inhibitors prevent cancer cells from repairing damaged DNA, leading to the accumulation of genetic damage and ultimately cell death. This targeted approach has become an important treatment option for patients whose tumors carry defects in DNA repair pathways.

Lynparza is among the world’s leading PARP inhibitors and remains widely used across multiple tumor types. The availability of lower-cost generic versions could increase competition, improve affordability, and expand patient access after patent protections and regulatory barriers are resolved.

What Tentative Approval Means

A tentative approval indicates that the FDA has determined NATCO’s abbreviated new drug application (ANDA) meets the agency’s standards for quality, manufacturing, safety, and bioequivalence. However, the product cannot receive final approval or enter the U.S. market until existing patent protections or regulatory exclusivity expire or any related legal disputes are resolved.

NATCO confirmed that Paragraph IV patent litigation involving Olaparib remains ongoing. The company’s ANDA was submitted under the Paragraph IV pathway, which allows generic manufacturers to challenge patents listed for a reference product.

Commercialization Strategy

Under the partnership agreement, NATCO will manufacture the generic Olaparib tablets, while Alembic Pharmaceuticals Limited will oversee U.S. distribution and commercialization following final FDA approval and resolution of the remaining legal barriers.

The collaboration combines NATCO’s capabilities in manufacturing complex generic medicines with Alembic’s established commercial infrastructure in the U.S. generics market.

Significant Market Opportunity and Portfolio Growth

According to industry sales data cited by NATCO, Lynparza tablets generated approximately USD 1.4 billion in U.S. sales during the 12 months ending March 2026, underscoring the commercial potential of a future generic launch.

The tentative approval also strengthens NATCO’s expanding portfolio of complex generic medicines, particularly in oncology, where the company continues to target high-value products facing patent expiry. The timing of commercial launch will depend on the outcome of the ongoing patent litigation and receipt of final FDA approval, positioning NATCO to enter an important segment of the U.S. oncology generics market once all regulatory and legal conditions are met.

Reference

NATCO receives Tentative Approval for Olaparib Tablets from the United States Food and Drug Administration (U.S. FDA)